{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:31:37Z","timestamp":1790127097918,"version":"4.0.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/s41590-017-0007-9","type":"journal-article","created":{"date-parts":[[2017,12,3]],"date-time":"2017-12-03T17:51:51Z","timestamp":1512323511000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8112-0853","authenticated-orcid":false,"given":"Barney S.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"7_CR1","unstructured":"World Health Organization. The Global Burden of Disease 2004. Part 4:Burden of Disease: DALYs (World Health Organization, 2004)."},{"key":"7_CR2","unstructured":"World Health Organization. World Health Statistics 2009. Cause-specific Mortality and Morbidity 47\u201357 (World Health Organization, 2004)."},{"key":"7_CR3","unstructured":"United Nations. Resolution adopted by the General Assembly on 25 September 2015. 70\/1. Transforming our world: the 2030 Agenda for Sustainable Development http:\/\/www.un.org\/ga\/search\/view_doc.asp?symbol=A\/RES\/70\/1&Lang=E (2015)."},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1108296","volume":"366","author":"AS Fauci","year":"2012","unstructured":"Fauci, A. S. & Morens, D. M. The perpetual challenge of infectious diseases. N. Engl. J. Med. 366, 454\u2013461 (2012).","journal-title":"N. Engl. J. Med."},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","volume":"329","author":"T Zhou","year":"2010","unstructured":"Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811\u2013817 (2010).","journal-title":"Science"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.1128\/JVI.00754-11","volume":"85","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85, 8954\u20138967 (2011).","journal-title":"J. Virol."},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1126\/science.1207532","volume":"333","author":"X Wu","year":"2011","unstructured":"Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593\u20131602 (2011).","journal-title":"Science"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","volume":"166","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza a viruses. Cell 166, 609\u2013623 (2016).","journal-title":"Cell"},{"key":"7_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep36298","volume":"6","author":"RF Villar","year":"2016","unstructured":"Villar, R. F. et al. Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation. Sci. Rep 6, 36298 (2016).","journal-title":"Sci. Rep"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1234150","volume":"340","author":"J Jardine","year":"2013","unstructured":"Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711\u2013716, https:\/\/doi.org\/10.1126\/science.1234150 (2013).","journal-title":"Science"},{"key":"7_CR11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029413","author":"SF Andrews","year":"2017","unstructured":"Andrews, S. F., Graham, B. S., Mascola, J. R. & McDermott, A. B. Is it possible to develop a \u201cuniversal\u201d influenza virus vaccine? Immunogenetic considerations underlying b-cell biology in the development of a pan-subtype influenza a vaccine targeting the hemagglutinin stem. Cold Spring Harb. Perspect. Biol. https:\/\/doi.org\/10.1101\/cshperspect.a029413 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med 21, 1065\u20131070 (2015).","journal-title":"Nat. Med"},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.cell.2016.07.029","volume":"166","author":"M Tian","year":"2016","unstructured":"Tian, M. et al. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell 166, 1471\u20131484 (2016).","journal-title":"Cell"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1126\/science.287.5453.607","volume":"287","author":"BH Hahn","year":"2000","unstructured":"Hahn, B. H., Shaw, G. M., De Cock, K. M. & Sharp, P. M. AIDS as a zoonosis: scientific and public health implications. Science 287, 607\u2013614 (2000).","journal-title":"Science"},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967\u20131976 (2003).","journal-title":"N. Engl. J. Med."},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra032498","volume":"349","author":"JS Peiris","year":"2003","unstructured":"Peiris, J. S., Yuen, K. Y., Osterhaus, A. D. & St\u00f6hr, K. The severe acute respiratory syndrome. N. Engl. J. Med. 349, 2431\u20132441 (2003).","journal-title":"N. Engl. J. Med."},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa044021","volume":"352","author":"K Ungchusak","year":"2005","unstructured":"Ungchusak, K. et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352, 333\u2013340 (2005).","journal-title":"N. Engl. J. Med."},{"key":"7_CR19","first-page":"97","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","unstructured":"Centers for Disease Control and Prevention (CDC). Outbreaks of avian influenza A (H5N1) in Asia and interim recommendations for evaluation and reporting of suspected cases\u2013United States, 2004. MMWR Morb. Mortal. Wkly. Rep. 53, 97\u2013100 (2004).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMp1506820","volume":"373","author":"SA Plotkin","year":"2015","unstructured":"Plotkin, S. A., Mahmoud, A. A. & Farrar, J. Establishing a global vaccine-development fund. N. Engl. J. Med. 373, 297\u2013300 (2015).","journal-title":"N. Engl. J. Med."},{"key":"7_CR21","doi-asserted-by":"publisher","unstructured":"Plotkin, S. A. Vaccines for epidemic infections and the role of CEPI. Hum. Vaccin. Immunother. http:\/\/dx.doi.org\/10.1080\/21645515.2017.1306615 (2017).","DOI":"10.1080\/21645515.2017.1306615"},{"key":"7_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrd4669","volume":"14","author":"M Slaoui","year":"2015","unstructured":"Slaoui, M. & Mullard, A. Moncef Slaoui. Nat. Rev. Drug Discov. 14, 452\u2013453 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/imr.12098","volume":"255","author":"BS Graham","year":"2013","unstructured":"Graham, B. S. Advances in antiviral vaccine development. Immunol. Rev. 255, 230\u2013242 (2013).","journal-title":"Immunol. Rev."},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaf8505","volume":"353","author":"K Stettler","year":"2016","unstructured":"Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823\u2013826 (2016).","journal-title":"Science"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"},{"key":"7_CR26","volume":"1","author":"MS Gilman","year":"2016","unstructured":"Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, eaaj1879 (2016).","journal-title":"Immunol."},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1128\/JVI.00555-11","volume":"85","author":"JS McLellan","year":"2011","unstructured":"McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788\u20137796 (2011).","journal-title":"J. Virol."},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1126\/science.aaf5316","volume":"352","author":"D Sirohi","year":"2016","unstructured":"Sirohi, D. et al. The 3.8 \u00c5 resolution cryo-EM structure of Zika virus. Science 352, 467\u2013470 (2016).","journal-title":"Science"},{"key":"7_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/31514","volume":"393","author":"R Wyatt","year":"1998","unstructured":"Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705\u2013711 (1998).","journal-title":"Nature"},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature09555","volume":"468","author":"JE Voss","year":"2010","unstructured":"Voss, J. E. et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468, 709\u2013712 (2010).","journal-title":"Nature"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/289366a0","volume":"289","author":"IA Wilson","year":"1981","unstructured":"Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3A resolution. Nature 289, 366\u2013373 (1981).","journal-title":"Nature"},{"key":"7_CR32","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1016\/j.vaccine.2015.06.117","volume":"33","author":"D Furman","year":"2015","unstructured":"Furman, D. & Davis, M. M. New approaches to understanding the immune response to vaccination and infection. Vaccine 33, 5271\u20135281 (2015).","journal-title":"Vaccine"},{"key":"7_CR33","first-page":"237","volume":"386","author":"PR Dormitzer","year":"2015","unstructured":"Dormitzer, P. R. Rapid production of synthetic influenza vaccines. Curr. Top. Microbiol. Immunol. 386, 237\u2013273 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1128\/JVI.02717-12","volume":"87","author":"MG Joyce","year":"2013","unstructured":"Joyce, M. G. et al. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. J. Virol. 87, 2294\u20132306 (2013).","journal-title":"J. Virol."},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1126\/science.1153263","volume":"319","author":"L Li","year":"2008","unstructured":"Li, L. et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319, 1830\u20131834 (2008).","journal-title":"Science"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrmicro1067","volume":"3","author":"S Mukhopadhyay","year":"2005","unstructured":"Mukhopadhyay, S., Kuhn, R. J. & Rossmann, M. G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13\u201322 (2005).","journal-title":"Nat. Rev. Microbiol."},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","volume":"78","author":"CB Buck","year":"2004","unstructured":"Buck, C. B., Pastrana, D. V., Lowy, D. R. & Schiller, J. T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751\u2013757 (2004).","journal-title":"J. Virol."},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"key":"7_CR40","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1126\/science.1219364","volume":"336","author":"NP King","year":"2012","unstructured":"King, N. P. et al. Computational design of self-assembling protein nanomaterials with atomic level accuracy. Science 336, 1171\u20131174 (2012).","journal-title":"Science"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature13404","volume":"510","author":"NP King","year":"2014","unstructured":"King, N. P. et al. Accurate design of co-assembling multi-component protein nanomaterials. Nature 510, 103\u2013108 (2014).","journal-title":"Nature"},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1016\/j.vaccine.2017.04.085","volume":"35","author":"SC Gilbert","year":"2017","unstructured":"Gilbert, S. C. & Warimwe, G. M. Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. Vaccine 35, 4461\u20134464 (2017).","journal-title":"Vaccine"},{"key":"7_CR43","doi-asserted-by":"crossref","unstructured":"M\u00fchlebach, M. D. Vaccine platform recombinant measles virus. Virus Genes (2017).","DOI":"10.1007\/s11262-017-1486-3"},{"key":"7_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz, A. & Sutter, G. Modified vaccinia virus ankara: history, value in basic research, and current perspectives for vaccine development. Adv. Virus Res 97, 187\u2013243 (2017).","journal-title":"Adv. Virus Res"},{"key":"7_CR45","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/biot.201400392","volume":"10","author":"CL Effio","year":"2015","unstructured":"Effio, C. L. & Hubbuch, J. Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles. Biotechnol. J 10, 715\u2013727 (2015).","journal-title":"Biotechnol. J"},{"key":"7_CR46","doi-asserted-by":"publisher","unstructured":"Suschak, J. J., Williams, J. A. & Schmaljohn, C. S. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum. Vaccin. Immunother. http:\/\/dx.doi.org\/10.1080\/21645515.2017.1330236 (2017).","DOI":"10.1080\/21645515.2017.1330236"},{"key":"7_CR47","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316\u20131327 (2017).","journal-title":"Mol. Ther."},{"key":"7_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2016.05.008","volume":"41","author":"JB Ulmer","year":"2016","unstructured":"Ulmer, J. B. & Geall, A. J. Recent innovations in mRNA vaccines. Curr. Opin. Immunol. 41, 18\u201322 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"7_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4161\/hv.8627","volume":"5","author":"JE Ledgerwood","year":"2009","unstructured":"Ledgerwood, J. E. & Graham, B. S. DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum. Vaccin 5, 623\u2013626 (2009).","journal-title":"Hum. Vaccin"},{"key":"7_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent, A. M. et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev. Vaccines 16, 55\u201363 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"7_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-chembioeng-060816-101514","volume":"8","author":"MR Prausnitz","year":"2017","unstructured":"Prausnitz, M. R. Engineering microneedle patches for vaccination and drug delivery to skin. Annu. Rev. Chem. Biomol. Eng. 8, 177\u2013200 (2017).","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"7_CR52","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/CVI.00162-06","volume":"13","author":"JE Martin","year":"2006","unstructured":"Martin, J. E. et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccine Immunol. 13, 1267\u20131277 (2006).","journal-title":"Clin. Vaccine Immunol."},{"key":"7_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/35046108","volume":"408","author":"NJ Sullivan","year":"2000","unstructured":"Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. & Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605\u2013609 (2000).","journal-title":"Nature"},{"key":"7_CR54","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.2447","volume":"17","author":"NJ Sullivan","year":"2011","unstructured":"Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med 17, 1128\u20131131 (2011).","journal-title":"Nat. Med"},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med 20, 1126\u20131129 (2014).","journal-title":"Nat. Med"},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","volume":"35","author":"Y Zhou","year":"2015","unstructured":"Zhou, Y. & Sullivan, N. J. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr. Opin. Immunol. 35, 131\u2013136 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"7_CR57","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee adenovirus vector Ebola vaccine. N. Engl. J. Med. 376, 928\u2013938 (2017).","journal-title":"N. Engl. J. Med."},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635\u20131646 (2016).","journal-title":"N. Engl. J. Med."},{"key":"7_CR59","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","volume":"16","author":"O De Santis","year":"2016","unstructured":"De Santis, O. et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study. Lancet Infect. Dis. 16, 311\u2013320 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"7_CR60","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","volume":"15","author":"A Huttner","year":"2015","unstructured":"Huttner, A. et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial. Lancet Infect. Dis. 15, 1156\u20131166 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"7_CR61","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/0035-9203(52)90021-7","volume":"46","author":"GW Dick","year":"1952","unstructured":"Dick, G. W. & Haddow, A. J. Uganda S virus; a hitherto unrecorded virus isolated from mosquitoes in Uganda. I. Isolation and pathogenicity. Trans. R. Soc. Trop. Med. Hyg. 46, 600\u2013618 (1952).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"7_CR62","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(16)00651-6","volume":"387","author":"S Cauchemez","year":"2016","unstructured":"Cauchemez, S. et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet 387, 2125\u20132132 (2016).","journal-title":"Lancet"},{"key":"7_CR63","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","volume":"375","author":"P Brasil","year":"2016","unstructured":"Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375, 2321\u20132334 (2016).","journal-title":"N. Engl. J. Med."},{"key":"7_CR64","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1056\/NEJMoa0805715","volume":"360","author":"MR Duffy","year":"2009","unstructured":"Duffy, M. R. et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N. Engl. J. Med. 360, 2536\u20132543 (2009).","journal-title":"N. Engl. J. Med."},{"key":"7_CR65","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2016.09.020","volume":"167","author":"TC Pierson","year":"2016","unstructured":"Pierson, T. C. & Graham, B. S. Zika virus: immunity and vaccine development. Cell 167, 625\u2013631 (2016).","journal-title":"Cell"},{"key":"7_CR66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/375291a0","volume":"375","author":"FA Rey","year":"1995","unstructured":"Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C. & Harrison, S. C. The envelope glycoprotein from tick-borne encephalitis virus at 2\u2009A resolution. Nature 375, 291\u2013298 (1995).","journal-title":"Nature"},{"key":"7_CR67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jcv.2012.08.024","volume":"55","author":"FX Heinz","year":"2012","unstructured":"Heinz, F. X. & Stiasny, K. Flaviviruses and their antigenic structure. J. Clin. Virol. 55, 289\u2013295 (2012).","journal-title":"J. Clin. Virol."},{"key":"7_CR68","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","volume":"29","author":"Y Van Gessel","year":"2011","unstructured":"Van Gessel, Y. et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(\u00ae)) induced neutralizing antibody titers. Vaccine 29, 5925\u20135931 (2011).","journal-title":"Vaccine"},{"key":"7_CR69","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","volume":"29","author":"JG Julander","year":"2011","unstructured":"Julander, J. G., Trent, D. W. & Monath, T. P. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 29, 6008\u20136016 (2011).","journal-title":"Vaccine"},{"key":"7_CR70","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1046\/j.1365-2249.1997.4311446.x","volume":"110","author":"TR Kreil","year":"1997","unstructured":"Kreil, T. R., Burger, I., Bachmann, M., Fraiss, S. & Eibl, M. M. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin. Exp. Immunol. 110, 358\u2013361 (1997).","journal-title":"Clin. Exp. Immunol."},{"key":"7_CR71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109\u2013113 (2015).","journal-title":"Nature"},{"key":"7_CR72","doi-asserted-by":"publisher","first-page":"18950","DOI":"10.1073\/pnas.1011036107","volume":"107","author":"B Kaufmann","year":"2010","unstructured":"Kaufmann, B. et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. USA 107, 18950\u201318955 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7_CR73","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1073\/pnas.1200566109","volume":"109","author":"R de Alwis","year":"2012","unstructured":"de Alwis, R. et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. USA 109, 7439\u20137444 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7_CR74","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2016.07.020","volume":"166","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. Structural basis of Zika virus-specific antibody protection. Cell 166, 1016\u20131027 (2016).","journal-title":"Cell"},{"key":"7_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1586\/14760584.2015.985661","volume":"14","author":"R \u0160mit","year":"2015","unstructured":"\u0160mit, R. & Postma, M. J. Review of tick-borne encephalitis and vaccines: clinical and economical aspects. Expert Rev. Vaccines 14, 737\u2013747 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"7_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/erv.11.7","volume":"10","author":"SB Halstead","year":"2011","unstructured":"Halstead, S. B. & Thomas, S. J. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines 10, 355\u2013364 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"7_CR77","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1001\/jama.300.8.960","volume":"300","author":"JE Staples","year":"2008","unstructured":"Staples, J. E. & Monath, T. P. Yellow fever: 100 years of discovery. J. Am. Med. Assoc 300, 960\u2013962 (2008).","journal-title":"J. Am. Med. Assoc"},{"key":"7_CR78","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","volume":"29","author":"B Guy","year":"2011","unstructured":"Guy, B. et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29, 7229\u20137241 (2011).","journal-title":"Vaccine"},{"key":"7_CR79","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro, S. R. et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195\u20131206 (2015).","journal-title":"N. Engl. J. Med."},{"key":"7_CR80","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","volume":"29","author":"AP Durbin","year":"2011","unstructured":"Durbin, A. P., Kirkpatrick, B. D., Pierce, K. K., Schmidt, A. C. & Whitehead, S. S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29, 7242\u20137250 (2011).","journal-title":"Vaccine"},{"key":"7_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005584","volume":"11","author":"SS Whitehead","year":"2017","unstructured":"Whitehead, S. S. et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl. Trop. Dis. 11, e0005584 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.21","volume":"1","author":"K Muthumani","year":"2016","unstructured":"Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines 1, 16021 (2016).","journal-title":"Npj Vaccines"},{"key":"7_CR83","doi-asserted-by":"crossref","unstructured":"Dowd, K. A. et\u00a0al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237\u2013240","DOI":"10.1126\/science.aai9137"},{"key":"7_CR84","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251 (2017).","journal-title":"Nature"},{"key":"7_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.016","volume":"169","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 169, 176 (2017).","journal-title":"Cell"},{"key":"7_CR86","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","volume":"370","author":"E Tauber","year":"2007","unstructured":"Tauber, E. et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370, 1847\u20131853 (2007).","journal-title":"Lancet"},{"key":"7_CR87","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nm.4322","volume":"23","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat. Med 23, 763\u2013767 (2017).","journal-title":"Nat. Med"},{"key":"7_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/srep46375","volume":"7","author":"K Sumathy","year":"2017","unstructured":"Sumathy, K. et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci. Rep 7, 46375 (2017).","journal-title":"Sci. Rep"},{"key":"7_CR89","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132 (2016).","journal-title":"Science"},{"key":"7_CR90","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"key":"7_CR91","first-page":"e00009","volume":"91","author":"TE Morrison","year":"2017","unstructured":"Morrison, T. E. & Diamond, M. S. Animal models of Zika virus infection, pathogenesis, and immunity. J. Virol. 91, e00009\u201317 (2017).","journal-title":"J. Virol."},{"key":"7_CR92","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","volume":"16","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Reports 16, 1485\u20131491 (2016).","journal-title":"Cell Reports"},{"key":"7_CR93","unstructured":"US Food & Drug Administration. Emergency Use Authorizations. https:\/\/www.fda.gov\/medicaldevices\/safety\/emergencysituations\/ucm161496.htm (2016)."},{"key":"7_CR94","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20564","volume":"540","author":"G Sapparapu","year":"2016","unstructured":"Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"7_CR95","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.chom.2016.05.009","volume":"19","author":"A Grant","year":"2016","unstructured":"Grant, A. et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe 19, 882\u2013890 (2016).","journal-title":"Cell Host Microbe"},{"key":"7_CR96","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1128\/JVI.01433-15","volume":"90","author":"AL Bailey","year":"2015","unstructured":"Bailey, A. L. et al. Zoonotic potential of simian arteriviruses. J. Virol. 90, 630\u2013635 (2015).","journal-title":"J. Virol."}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-017-0007-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-017-0007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-017-0007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:44:51Z","timestamp":1733957091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-017-0007-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1038\/s41590-017-0007-9","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]},"assertion":[{"value":"11 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}